Conclusive link between genetics and clinical response to warfarin uncovered
Higher early rates of bleeding with warfarin linked to genetic differences; newer drug provides greater early safety for patients with these genetic variants
2015-03-11
(Press-News.org) In a study published in The Lancet on March 10, researchers from Brigham and Women's Hospital (BWH) report that patients with a genetic sensitivity to warfarin - the most widely used anticoagulant for preventing blood clots - have higher rates of bleeding during the first several months of treatment and benefited from treatment with a different anticoagulant drug. The analyses from the TIMI Study Group, suggest that using genetics to identify patients who are most at risk of bleeding, and tailoring treatment accordingly, could offer important safety benefits, particularly in the first 90 days of treatment.
"We were able to look at patients from around the world who were being treated with warfarin and found that certain genetic variants make a difference for an individual's risk for bleeding," said Jessica L. Mega, MD, MPH, a cardiologist at BWH, senior investigator in the TIMI Study Group and lead author of the paper. "For these patients who are sensitive or highly sensitive responders based on genetics, we observed a higher risk of bleeding in the first several months with warfarin, and consequently, a big reduction in bleeding when treated with the drug edoxaban instead of warfarin."
Warfarin has been in clinical use for 60 years and genetics has been thought to influence an individual's sensitivity to the drug. The FDA label for warfarin notes that genetic variants in two genes - CYP2C9 and VKORC1 - can assist in determining the right warfarin dosage for an individual. But a conclusive link between variation in these two genes and bleeding has been debated. By leveraging data from their ENGAGE AF-TIMI 48 trial - an international, randomized, double-blind trial in which patients with atrial fibrillation received either a higher dose of edoxaban, a lower dose of edoxaban or warfarin to prevent blood clots from forming in the heart and leading to stroke - the TIMI investigators were able to observe important connections between genetic differences and patient outcomes. The trial represents the largest study of this kind to date and included nearly three years of follow-up with participants.
In ENGAGE-TIMI 48, patients were randomly assigned treatment and followed over time. The research team divided 14,000 study participants into three categories based on genetic makeup: normal responders, sensitive responders or highly sensitive responders. During the first 90 days, sensitive and highly sensitive responders who received warfarin experienced significantly higher rates of bleeding compared to normal responders. As a result, during this early time period, edoxaban was more effective than warfarin at reducing bleeding in sensitive and highly sensitive responders.
"These findings demonstrate the power of genetics in personalizing medicine and tailoring specific therapies for our patients," said Marc S. Sabatine, MD, MPH, a cardiologist at BWH, Chairman of the TIMI Study Group and senior author of the paper.
Warfarin remains the most common anticoagulant in part due to economics and availability, but several novel oral anticoagulants (NOACs), including dabigatran, rivaroxaban and apixaban, have entered the market. Edoxaban, a Xa inhibitor, received FDA approval for stroke prevention in atrial fibrillation earlier this year based on the results of the ENGAGE AF-TIMI 48 trial.
INFORMATION:
ENGAGE AF-TIMI 48 was supported by research grants from Daiichi Sankyo. Full funding information, including all author disclosures, can be found in the full text of the article.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in Massachusetts and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials group. For more information, resources and to follow us on social media, please visit BWH's online newsroom.
ELSE PRESS RELEASES FROM THIS DATE:
2015-03-10
VANCOUVER, Wash.--Washington State University researchers have found a mechanism in the brain that facilitates the pathologically powerful role of memory in drug addiction. Their discovery opens a new area of research for targeted therapy that would alter or disable the mechanism and make drug addiction less compulsive.
Turning off the mechanism is "diminishing the emotional impact or the emotional content of the memory, so it decreases the motivation to relapse," said Barbara Sorg, a professor of neuroscience at Washington State University, Vancouver. Her findings appear ...
2015-03-10
Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have uncovered new clues about the risk of cancer from low-dose radiation, which in this research they define as equivalent to 100 millisieverts or roughly the dose received from ten full-body CT scans.
They studied mice and found their risk of mammary cancer from low-dose radiation depends a great deal on their genetic makeup. They also learned key details about how genes and the cells immediately surrounding a tumor (also called the tumor microenvironment) affect cancer ...
2015-03-10
La Jolla, Calif., March 9, 2015 - Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.
"Our study indicates that a protein called RNF5 ...
2015-03-10
McGill researchers have discovered, for the first time, the importance of a key epigenetic regulator in the development of the hippocampus, a part of the brain associated with learning, memory and neural stem cells. Epigenetic regulators change the way specific genes function without altering their DNA sequence. By working with mutant mice as models, the research team, led by Prof. Xiang-Jiao Yang, of McGill's Goodman Cancer Center & Department of Medicine, McGill University Health Center, was able to link the importance of a specific epigenetic regulator known as BRPF1 ...
2015-03-10
The combination of stress and heavy depression can significantly increase heart patient's risk of death or heart attack, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
The study examined the effect of high stress levels and high depressive symptoms among nearly 5,000 heart patients. Researchers concluded that risk is amplified when both conditions are present, thus validating the concept of a "psychosocial perfect storm."
"The increase in risk accompanying high stress and high depressive symptoms ...
2015-03-10
A review of nutrition and weight-loss interventions for people with impaired mobility found strategies are sorely lacking for people with neurological disabilities, according to a team of researchers from Case Western Reserve University and Cleveland Clinic.
Interventions are overwhelmingly geared toward muscular disorders, leaving a gap in approaches that could help people with neurological disabilities become more active, eat healthier and lose weight, they conclude.
The researchers wanted to learn more about interventions for people who, because of limited mobility, ...
2015-03-10
Identifying loss of dignity and lack of respectful treatment as preventable harms in health care, researchers at Johns Hopkins have taken on the ambitious task of defining and ensuring respectful care in the high-stakes environment of the intensive care unit (ICU). Their novel, multi-method approach is presented in a dedicated supplement to the journal Narrative Inquiry in Bioethics.
"In health care the importance of respect and dignity is often invoked, but has not been clearly defined in regard to treatment in the ICU," says Jeremy Sugarman, the Harvey M. Meyerhoff ...
2015-03-10
MOUNTAIN VIEW, Calif., March 10, 2015 -- Today marked the publication of the first ever genome-wide association study of rosacea, a common and incurable skin disorder. Led by Dr. Anne Lynn S. Chang of Stanford University's School of Medicine, and co-authored by 23andMe, the study is the first to identify genetic factors for this condition.
Rosacea (pronounced roh-ZAY-sha) is estimated to affect more than 16 million people in the United States alone1. Symptoms typically include redness, visible blood vessels, and pimple-like sores on the skin of the central face, and ...
2015-03-10
ANN ARBOR--Each year, millions of people lose billions of dollars in NCAA March Madness basketball pools. Still, most return the following year for another pummeling.
But flipping a coin yields better results than carefully selecting brackets, says Dae Hee Kwak, assistant professor of sport management at the University of Michigan School of Kinesiology.
"I completed my own (informal) bracket alongside our study by literally flipping a coin 63 times," Kwak said. "I wanted to see if this outperformed the hard thought-out selections made by the study participants in ...
2015-03-10
The sugar industry used several tactics to influence the setting of research priorities for the 1971 US National Caries Program (NCP), according to a study published by Cristin Kearns, Stanton Glantz and Laura Schmidt from the University of California San Francisco, US, in this week's PLOS Medicine.
The researchers analyzed an archive of 319 internal sugar industry documents from 1959 to 1971 (the "Roger Adams papers") and US National Institute of Dental Research (NIDR) documents to explore how the sugar industry sought to influence the setting of research priorities ...
LAST 30 PRESS RELEASES:
[Press-News.org] Conclusive link between genetics and clinical response to warfarin uncovered
Higher early rates of bleeding with warfarin linked to genetic differences; newer drug provides greater early safety for patients with these genetic variants
